Not a good buy right now: short-term technicals are still weak and the pattern-based forecast skews bearish over the next day/week.
Price is hovering just above near-term support (~4.92); risk of a breakdown is meaningful, and there’s no proprietary buy signal to override that.
Options positioning looks call-heavy, but actual trading volume is near-zero and implied volatility is extremely elevated into upcoming earnings, making timing/entry unattractive for an impatient buyer.
Wall Street is generally constructive, but near-term upside vs. risk looks limited given mixed fundamentals and margin/EPS pressure.
Technical Analysis
Trend/pressure: MACD histogram is negative (-0.0574) though contracting, suggesting bearish momentum is easing but not yet reversed.
RSI(6)=35.245: close to oversold territory, which can support a bounce, but it’s not a confirmed reversal signal.
Moving averages: converging MAs imply consolidation; a decisive break is likely, but direction is not confirmed.
Key levels: Support S1=4.918 (very close to current 4.985), then S2=4.72. Resistance at Pivot=5.239, then R1=5.56.
Probabilistic trend read: similar-pattern analysis shows ~60% chance of -2.17% next day and -4.32% next week (bearish near-term), with a modest +1.9% next month (potential rebound later).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put/Call Open Interest ratio = 0.12 (call open interest dominates; typically bullish/optimistic positioning).
Trading activity: Today’s options volume is only 1 contract (puts 0), so sentiment signal from volume is weak despite the call-heavy OI.
Volatility: 30D IV ~434.82 vs historical volatility ~44.96 — extremely elevated implied move expectations (often seen ahead of catalysts like earnings).
IV context: IV percentile ~39.84 / IV rank ~49.78 suggests IV is not at the absolute extreme vs its own history, but the absolute level is still very high.
Setup implication: options are pricing large uncertainty; for stock entry, this often coincides with choppy/unstable price action into catalysts.
Technical Summary
Sell
7
Buy
6
Positive Catalysts
Upcoming earnings: QDEC 2025 earnings on 2026-02-26 after hours (a clear event catalyst; guidance/trajectory could move the stock).
Analyst tone remains positive overall (Buy/Overweight maintained), and TD Cowen recently raised its price target (to $5).
RSI near oversold and MACD bearish momentum contracting: conditions that can precede a technical bounce if support holds.
Neutral/Negative Catalysts
Extremely high implied volatility signals uncertainty into earnings; the stock can swing sharply against a rushed entry.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $52.293M, +1.54% YoY (low growth).
Profitability: Net income -$5.478M, down -682.15% YoY (loss widened materially).
EPS: -$0.04, down -500% YoY.
Gross margin: 52.69%, down -6.45% YoY (margin compression is a negative trend).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent changes: TD Cowen (2026-01-08) raised PT to $5 from $4 and reiterated Buy; Piper Sandler (2025-11-11) lowered PT to $7.50 from $8 and reiterated Overweight.
Trend summary: ratings remain positive, but price targets have been adjusted and near-term conviction appears tied to future guidance/sector recovery.
Wall Street pros: constructive long-term framework narrative and potential upside if guidance improves.
Wall Street cons: recent results/targets reflect tempered near-term expectations; with CTKB near ~$5, TD’s $5 target implies limited upside without a catalyst-driven re-rate.
Influential trading: hedge fund and insider activity flagged as neutral; no recent congress trades reported in the last 90 days.
Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 6.17 USD with a low forecast of 5 USD and a high forecast of 7.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast CTKB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTKB is 6.17 USD with a low forecast of 5 USD and a high forecast of 7.5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 4.500
Low
5
Averages
6.17
High
7.5
Current: 4.500
Low
5
Averages
6.17
High
7.5
TD Cowen
Buy
maintain
$4 -> $5
AI Analysis
2026-01-08
Reason
TD Cowen
Price Target
$4 -> $5
AI Analysis
2026-01-08
maintain
Buy
Reason
TD Cowen raised the firm's price target on Cytek Biosciences to $5 from $4 and keeps a Buy rating on the shares. The firm adjusted price targets in the diagnostic tools group group as part of a Q4 preview. Investor sentiment continues to inflect upward with 2026 guidance updates "key for positioning within the sector recovery," the analyst tells investors in a research note. TD is most positive on stocks "with clear multi-year frameworks and multiple avenues for upside to derisked growth assumptions."
Piper Sandler
Overweight
downgrade
$8
2025-11-11
Reason
Piper Sandler
Price Target
$8
2025-11-11
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Cytek Biosciences to $7.50 from $8 keeps an Overweight rating on the shares. The firm cites the company's quarterly results for the price target change.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTKB
